ScreenerHero

SIGASIGA Technologies, Inc.

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · siga.com
3.040USD-2.25%Mkt Cap: 218.42M $P/E: —

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. The company's lead product is TPOXX, an antiviral drug for the treatment of human smallpox d…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.19BUSDP/E 23.7
TAK
Takeda Pharmaceutical Co. Ltd.
$58.06BUSD
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.98BUSDP/E 20.4
TEVA
Teva Pharmaceutical Industries Limited
$43.51BUSDP/E 62.2
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
ZTS
Zoetis Inc.
$32.12BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.01BUSDP/E 18.4
VTRS
Viatris, Inc.
$18.75BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.34BUSDP/E 117.3
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
NBIX
Neurocrine Biosciences, Inc.
$15.51BUSDP/E 22.3
ELAN
Elanco Animal Health Incorporat
$11.98BUSD
RDY
Dr. Reddy's Laboratories Ltd
$10.15BUSDP/E 29.7
KRK
Krka, d. d.
$8.66BUSDP/E 19.0
ALKS
Alkermes plc
$8.11BUSDP/E 127.2
HIMS
Hims & Hers Health, Inc.
$7.88BUSD
LNTH
Lantheus Holdings Inc
$6.53BUSDP/E 23.9
AMRX
Amneal Pharmaceuticals, Inc. Class A
$6.24BUSDP/E 37.3
LQDA
Liquidia Corporation
$6.14BUSDP/E 49.0
KNSA
Kiniksa Pharmaceuticals, Ltd.
$6.08BUSDP/E 79.8

Key Statistics

Company
Market Cap218.42M $
Enterprise Value96.25M $
Revenue (TTM)53.66M $
Gross Profit64.87M $
Net Income (TTM)23.28M $
Revenue/Share0.7490 USD
Last Price3.040 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees49
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)2.75
PEG3.37
EV/EBITDA-9.13
EV/Revenue1.79
P/S3.98
P/B1.29
EPS (TTM)-0.04
EPS (Forward)1.08
52W Range
2.8303% of range9.450
52W High9.450 USD
52W Low2.830 USD
Profitability
Gross Margin68.59%
Oper. Margin33.91%
EBITDA Margin-19.66%
Profit Margin24.61%
ROE11.71%
ROA10.61%
Growth
Revenue Growth-49.50%
Earnings Growth-65.30%
Cash Flow & Leverage
Operating CF43.47M $
CapEx (TTM)355.01K $
FCF Margin-44.70%
FCF Yield-10.98%
Net Debt-117.15M $
Net Debt/EBITDA11.11
Balance Sheet
Debt/Equity0.00
Current Ratio21.72
Quick Ratio15.90
Book Value/Sh2.301 USD
Cash/Share1.637 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateApr 7, 2026
Pay DateApr 23, 2026
Analyst Consensus
Rating0.0 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.71.85M
Float41.13M
Insiders42.73%
Institutions50.47%
Short Interest
Short Ratio4.6d
Short % Float7.94%
Short % Out.5.14%
Shares Short3.69M
Short (prev mo.)3.46M
Technical
SMA 503.538 (-14.1%)
SMA 2005.189 (-41.4%)
Beta0.89
S&P 52W Chg18.16%
Avg Vol (30d)762.67K
Avg Vol (10d)668.99K
Technical Indicators
RSI (14)41.2
MACD-0.1693
MACD Signal-0.1973
MACD Hist.+0.0280
BB Upper3.398 USD
BB Middle3.099 USD
BB Lower2.799 USD
BB Width19.36%
ATR (14)0.1532 USD
Vol Ratio (20d)1.29x